Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» September 2010
September 2010
Reata-Abbott deal may be worth $800M-plus
Reata-Abbott deal may be worth $800M-plus
Bizjournals.com
Abbott Laboratories
Reata
drug development
Big Pharma's Challenge: Figuring out China
Big Pharma's Challenge: Figuring out China
CNN/Fortune
China
Big Pharma
Pfizer
GSK
Sanofi
FDA Restricts Glaxo Diabetes Drug Avandia
FDA Restricts Glaxo Diabetes Drug Avandia
TheStreet.com
FDA
diabetes
Avandia
GSK
Will There Be Generic User Fees? Ramsey Explains
Will There Be Generic User Fees? Ramsey Explains
Pharmalot
generics
FDA
Mylan
AZ/Rigel RA drug hits PhIIb paydirt
AZ/Rigel RA drug hits PhIIb paydirt
Fierce Biotech
Rigel
rheumatoid arthritis
AstraZeneca
Did drugmaker hide birth control patch risks?
Did drugmaker hide birth control patch risks?
MSNBC
JNJ
birth control patch
Ortho Evra
U.S. sees bowel risk in early Glaxo vaccine data
U.S. sees bowel risk in early Glaxo vaccine data
Reuters
GSK
vaccines
Rotarix
rotavirus
Restructuring at Abbott Labs
Restructuring at Abbott Labs
Yahoo/Zacks.com
Abbott Laboratories
restructuring
Biosimilars: This Decade's Most Disruptive Technology
Biosimilars: This Decade's Most Disruptive Technology
PharmExec
biosimilars
Third Rock leads $30M round for antibody upstart CytomX
Third Rock leads $30M round for antibody upstart CytomX
Fierce Biotech
CytomX
venture capital
antibodies
Pages
« first
‹ previous
…
8
9
10
11
12
13
14
15
16
…
next ›
last »